Italia markets closed
FTSE MIB
35.398,82 -11,31 (-0,03%) Dow Jones
40.003,59 +134,21 (+0,34%) Nasdaq
16.685,97 -12,35 (-0,07%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
80,00 +0,77 (+0,97%) Bitcoin EUR
61.337,12 -242,51 (-0,39%)
NBIX Nov 2024 175.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:39AM EDT. Mercato aperto.
| Chiusura precedente | 3,0000 |
| Aperto | 3,0000 |
| Denaro | 1,6000 |
| Lettera | 6,1000 |
| Prezzo d'esercizio | 175,00 |
| Scadenza | 2024-11-15 |
| Min-Max giorno | 3,0000 - 3,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.